drugset / Trial / NCT01227239

Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting

NCT01227239

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of S-1 and oxaliplatin combined with radiation by Phase I/II study. The purpose of this study is as follows, * In phase I, to determine the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD). * In phase II, to evaluate the antitumor effect (pCR rate) and the safety .

Timeline

Start
2010-09
Primary completion
2013-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 40 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 50 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 60 mg/m2 Intravenous
Subject S-1 Small molecule 40 mg/m2 Oral

Indications